PACIFIC BIO CA (P09 BE) stock market data APIs
€1.4921
0(0%)
as of November 7, 2025
Try our APIs with
free plan!
PACIFIC BIO CA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for P09.BE.
Prev. Close
1.4921
Open
1.4921
High
1.4921
Low
1.4921
52 wk Range
0.7964-2.2545
Market Cap
4 079 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PACIFIC BIO CA data using free add-ons & libraries
Get PACIFIC BIO CA Fundamental Data
PACIFIC BIO CA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PACIFIC BIO CA News
New
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders in Pacific Biosciences of California, Inc. (NASDAQ:PACB) had a terrible week, as shares crashed 25% to US$1.76 in the week since its latest third-quarter results. The results weren't stel...
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 12 cents in third-quarter 2025, narrower than the year-ago adjusted loss of 17 cents pe...
PACB Q3 Deep Dive: Consumable Strength Offsets Instrument Headwinds, Clinical Expansion in Focus
Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of ...
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics
Pacific Biosciences of California (PACB) reported $38.44 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 3.8%. EPS of -$0.12 for the same period compa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
